Cell therapy · developed by Lisata Therapeutics
CLBS14 is an autologous cell therapy made of CD34+ cells mobilized from the bone marrow with G-CSF, selected from apheresis product and delivered as intramyocardial injections into areas of myocardial ischemia. It is studied in myocardial ischemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01508910 | Phase 3 | Chronic Myocardial Ischemia | Completed | LSTA |
| NCT00300053 | Phase 2 | Myocardial Ischemia | Completed | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myocardial Ischemia
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →